ReviewAnnals of translational medicine2018
Old and new insights into the diagnosis of hereditary spherocytosis.
Review in Annals of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Differential Diagnosis of Anemia Using the Erythrocyte Filterability Method.International journal of molecular sciences · 2026Article
- Identification of a novel hereditary spherocytosis gene mutation in a Chinese child with α-globin gene triplication.MedScience · 2026Article
- Clinical Characteristics and Gene Mutations of Hereditary Spherocytosis in 59 Chinese Children.Molecular genetics & genomic medicine · 2026Article
- Clinical evaluation and comparative study of a fully automated erythrocyte osmotic fragility analysis system based on scatter turbidimetry.Scientific reports · 2026Article
- Feasibility of Intensive Chemotherapy in Hereditary Spherocytosis.Hematology reports · 2025Article
- Two Variants of theBiomedicines · 2025Article
- Hereditary spherocytosis concomitant with JAK2V617F-positive primary myelofibrosis: a case report.Frontiers in oncology · 2025Article
- An overview of hereditary spherocytosis and the curative effects of splenectomy.Frontiers in physiology · 2025Review
- Clinical characteristics of hereditary spherocytosis with red blood cell membrane protein gene variants.Frontiers in pediatrics · 2025Article
- Article
- Severe hepatic sinusoidal obstruction syndrome in a patient with Wilms tumor and hereditary spherocytosis.International cancer conference journal · 2024Article
- Clinical and genetic diagnosis for 26 paitents with hereditary spherocytosis.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Novel Variant of theBiomedicines · 2023Article
- Anemia and Associated Risk Factors in Pediatric Patients.Pediatric health, medicine and therapeutics · 2023Review
- Associations and Disease-Disease Interactions of COVID-19 with Congenital and Genetic Disorders: A Comprehensive Review.Viruses · 2022Review
- Identification of a novel ANK1 mutation in hereditary spherocytosis co-existing with BWS.Molecular genetics & genomic medicine · 2022Article
- The diagnostic protocol for hereditary spherocytosis-2021 update.Journal of clinical laboratory analysis · 2021Review
- Identification of a Novel Mutation of β-Spectrin in Hereditary Spherocytosis Using Whole Exome Sequencing.International journal of molecular sciences · 2021Article
- Severe Presentation of Congenital Hemolytic Anemias in the Neonatal Age: Diagnostic and Therapeutic Issues.Diagnostics (Basel, Switzerland) · 2021Review
- Clinical profiles and diagnostic challenges in 1158 children with rare hepatobiliary disorders.Pediatric research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary spherocytosis (HS) belongs to the group of congenital hemolytic anemias resulting from plasma membrane protein deficiency. When diagnosed too late, HS bares the risk of long-term complications including gall stones and severe anemia. Here, there are discussed advances in HS screening and diagnostics, with a particular focus on methodologies, most of which are available in clinical laboratories worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.